Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [21] Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Matsuo, Norikazu
    Tokito, Takaaki
    Kinoshita, Takashi
    Yamada, Kazuhiko
    Sasada, Tetsuro
    Akiba, Jun
    Hoshino, Tomoaki
    ONCOTARGET, 2017, 8 (37) : 61618 - 61625
  • [22] Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Cheng, Ying
    Li, Hui
    Zhang, Liang
    Liu, Jing-Jing
    Yang, Chang-Liang
    Zhang, Shuang
    CHINESE MEDICAL JOURNAL, 2021, 134 (15) : 1780 - 1788
  • [23] B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma
    Yamada, Takehiro
    Miki, Yasuhiro
    Suzuki, Miho
    Kondoh, Osamu
    Saito-Koyama, Ryoko
    Ono, Katsuhiko
    Okada, Yoshinori
    Sasano, Hironobu
    CANCER MEDICINE, 2022, 11 (02): : 479 - 491
  • [24] Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer
    Kawachi, Hayato
    Fujimoto, Daichi
    Yamashita, Daisuke
    Fukuoka, Junya
    Kitamura, Yuka
    Hosoya, Kazutaka
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Date, Naoki
    Sakanoue, Ichiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2019, 39 (05) : 2561 - 2567
  • [25] Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer
    Sepesi, Boris
    Cuentas, Edwin Parra
    Canales, Jaime Rodriguez
    Behrens, Carmen
    Correa, Arlene M.
    Vaporciyan, Ara
    Weissferdt, Annikka
    Kalhor, Neda
    Moran, Cesar
    Swisher, Stephen
    Wistuba, Ignacio
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2017, 29 (03) : 408 - 415
  • [26] Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience
    Takeda, Maiko
    Kasai, Takahiko
    Naito, Maiko
    Tamiya, Akihiro
    Taniguchi, Yoshihiko
    Saijo, Nobuhiko
    Naoki, Yoko
    Okishio, Kyoichi
    Shimizu, Shigeki
    Kojima, Kensuke
    Nagoya, Akihiro
    Sakamoto, Tetsuki
    Utsumi, Tomoki
    Yoon, Hyung-Eun
    Matsumura, Akihide
    Atagi, Shinji
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [27] Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer
    Hata, Akito
    Katakami, Nobuyuki
    Nanjo, Shigeki
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Yoshida, Hiroshi
    Zama, Kota
    Imai, Yukihiro
    Hirata, Yukio
    ONCOTARGET, 2017, 8 (69) : 113807 - 113816
  • [28] Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater
    Jodai, Takayuki
    Saruwatari, Koichi
    Ikeda, Tokunori
    Moriyama, Eiji
    Kashiwabara, Kosuke
    Shingu, Naoki
    Iyonaga, Kazuhiro
    Inaba, Megumi
    Ajishi, Yusuke
    Honda, Chiharu
    Hirosako, Susumu
    Maruyama, Hirotaka
    Kakiuchi, Yosuke
    Eida, Hirofumi
    Tomita, Yusuke
    Saeki, Sho
    Ichiyasu, Hidenori
    Sakagami, Takuro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 78 - 86
  • [29] Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition
    Liang, Wenhua
    Guo, Minzhang
    Pan, Zhenkui
    Cai, Xiuyu
    Li, Caichen
    Zhao, Yi
    Liang, Hengrui
    Yang, Haiying
    Wang, Zhen
    Chen, Wenting
    Xu, Chuhong
    Yang, Xinyun
    Sun, Jianyu
    He, Ping
    Gu, Xia
    Yin, Weiqiang
    He, Jianxing
    CANCER SCIENCE, 2019, 110 (06) : 2014 - 2021
  • [30] Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer
    Kato, Yasuhiro
    Kashima, Jumpei
    Watanabe, Kageaki
    Yomota, Makiko
    Zenke, Yositaka
    Okuma, Yusuke
    Hosomi, Yukio
    Gemma, Akihiko
    Seike, Masahiro
    Okamura, Tatsuru
    ANTICANCER RESEARCH, 2018, 38 (02) : 1077 - 1083